Pfizer: starts phase 2b/3 trial in autoimmune skin disease
(CercleFinance.com) - Pfizer said that it has started a phase 2b/3 clinical trial for an experimental treatment of patients with moderate-to-severe alopecia areata, a chronic autoimmune skin disease that causes hair loss.
The study will enroll an estimated 660 adults and adolescents who have 50% or greater scalp hair loss, the US drugmaker said.
Including this oral drug program, Pfizer now has several kinase programs in the clinic with studies spanning chronic autoimmune and inflammatory conditions, such as rheumatology, gastrointestinal disorders and dermatology.
Copyright (c) 2019 CercleFinance.com. All rights reserved.